Cargando…
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion
A Current challenge in prostate cancer treatment is how to differentiate aggressive disease from indolent prostate cancer. There is an urgent need to identify markers that would accurately distinguish indolent prostate cancer from aggressive disease. The aim of this study was to evaluate the role of...
Autores principales: | Brown-Clay, Joshua D., Shenoy, Deepika N., Timofeeva, Olga, Kallakury, Bhaskar V., Nandi, Asit K., Banerjee, Partha P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558173/ https://www.ncbi.nlm.nih.gov/pubmed/25909225 |
Ejemplares similares
-
Erratum: PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion
por: Brown-Clay, Joshua D., et al.
Publicado: (2016) -
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
por: Zhu, Kejing, et al.
Publicado: (2022) -
PBK/TOPK Expression Predicts Prognosis in Oral Cancer
por: Chang, Chin-Fang, et al.
Publicado: (2016) -
PBK/TOPK: A Therapeutic Target Worthy of Attention
por: Han, Ziping, et al.
Publicado: (2021) -
PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential
por: Huang, Hai, et al.
Publicado: (2021)